{"filing":{"accession_number":"0001213900-26-085420","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ea030069702-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026085420/ea030069702-6k_scisparc.htm"},"events":[{"id":24053,"run_id":21755,"accession_number":"0001213900-26-085420","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Yale Child Study Center and other sites, representing a material advancement in the company's drug development program for Tourette Syndrome treatment. While the disclosure is operational in nature (a clinical trial milestone), it does not fit the specific `earnings_release` category (no financial results) nor other discrete event types. The Phase IIb launch, building on positive Phase IIa results showing 21% average tic reduction, constitutes a significant clinical and strategic milestone that would affect a reasonable investor's assessment of the registrant's pipeline progress and commercial prospects.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-08-05","form":"6-K","submitted_at":null,"items":[{"id":24447,"accession_number":"0001213900-26-085420","item_number":"EX-99.1","item_title":"ea030069702ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Yale Child Study Center and other sites, representing a material advancement in the company's drug development program for Tourette Syndrome treatment. While the disclosure is operational in nature (a clinical trial milestone), it does not fit the specific `earnings_release` category (no financial results) nor other discrete event types. The Phase IIb launch, building on positive Phase IIa results showing 21% average tic reduction, constitutes a significant clinical and strategic milestone that would affect a reasonable investor's assessment of the registrant's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:00:49.385471+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24447,"accession_number":"0001213900-26-085420","item_number":"EX-99.1","item_title":"ea030069702ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Yale Child Study Center and other sites, representing a material advancement in the company's drug development program for Tourette Syndrome treatment. While the disclosure is operational in nature (a clinical trial milestone), it does not fit the specific `earnings_release` category (no financial results) nor other discrete event types. The Phase IIb launch, building on positive Phase IIa results showing 21% average tic reduction, constitutes a significant clinical and strategic milestone that would affect a reasonable investor's assessment of the registrant's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:00:49.385471+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-08-05"}]}